Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EBIT (2020 - 2026)

Barinthus Biotherapeutics filings provide 7 years of EBIT readings, the most recent being -$6.1 million for Q1 2026.

  • On a quarterly basis, EBIT rose 70.51% to -$6.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$56.0 million, a 21.81% increase, with the full-year FY2025 number at -$70.6 million, down 3.8% from a year prior.
  • EBIT hit -$6.1 million in Q1 2026 for Barinthus Biotherapeutics, up from -$11.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $13.2 million in Q2 2022 to a low of -$26.3 million in Q2 2023.
  • Median EBIT over the past 5 years was -$16.9 million (2024), compared with a mean of -$13.7 million.
  • Biggest five-year swings in EBIT: soared 230.71% in 2022 and later tumbled 3385.02% in 2023.
  • Barinthus Biotherapeutics' EBIT stood at -$25.1 million in 2022, then rose by 20.34% to -$20.0 million in 2023, then decreased by 17.02% to -$23.4 million in 2024, then skyrocketed by 50.56% to -$11.6 million in 2025, then surged by 47.47% to -$6.1 million in 2026.
  • The last three reported values for EBIT were -$6.1 million (Q1 2026), -$11.6 million (Q4 2025), and -$15.1 million (Q3 2025) per Business Quant data.